TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02024282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention and parent leaflet
Description: Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.~We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Finger Pulse Oximeter
Description: All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Finger Pulse Oximeter
Description: All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Finger Pulse Oximeter
Description: All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.

Intervention type: DEVICE
Group type: OTHER
Intervention: Finger Pulse Oximeter
Description: All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
Study: NCT03391791

Intervention type: GENETIC
Intervention: Genetically engineered T Cell Receptors
Description: No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study: NCT00052897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HspE7
Study: NCT03633058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: oral ketamine dosed twice daily for 5 days
Study: NCT02560181

Intervention type: RADIATION
Group type: OTHER
Intervention: HDR brachytherapy
Description: Whole gland salvage
Study: NCT03034200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 625mg ONC201 will be given on two consecutive days each week
Study: NCT02901561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol 200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol 400
Study: NCT04413708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3-T PrEP Adherence App
Description: P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar.
Study: NCT02644057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
Study: NCT00191698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00521352

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Strong electromagnetic field (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
Study: NCT04511741

Intervention type: OTHER
Intervention: no intervention, it is an observational study.
Description: no intervention, it is an observational study.

Intervention type: OTHER
Intervention: no intervention, it is an observational study.
Description: no intervention, it is an observational study.
Study: NCT01813357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: encapsulated tablet 20mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm included to maintain blinding
Study: NCT02362763

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
Study: NCT03292029

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: T50 Calcification Inhibition Test (CIT)
Description: Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
Study: NCT01505803

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc supplements
Description: Participants will receive 40 mg of zinc each day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc supplements
Description: Participants will receive 40 mg of zinc each day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 supplements
Description: Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 supplements
Description: Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo supplements
Description: Participants will receive placebo supplements each day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplements
Description: Participants will receive placebo supplements each day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo supplements
Description: Participants will receive placebo supplements each day for 12 weeks.
Study: NCT04412239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centred advice on Telephone Consultation in TB Patients:
Description: The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
Study: NCT03034200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 625mg ONC201 will be given on two consecutive days each week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 625mg ONC201 will be given on two consecutive days each week
Study: NCT00526045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922 2 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922 2 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922 2 mg/m2
Study: NCT03238196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: 4mg - 8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: 4mg - 8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg
Study: NCT03701334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy
Description: ET will be administered according to the local clinical guidelines and current local prescribing information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: ET will be administered according to the local clinical guidelines and current local prescribing information
Study: NCT04341012

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath sample
Description: Analysis of volatile organic compounds in breath

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath sample
Description: Analysis of volatile organic compounds in breath

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath sample
Description: Analysis of volatile organic compounds in breath

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath sample
Description: Analysis of volatile organic compounds in breath
Study: NCT02025010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Abiraterone acetate is a selective and irreversible inhibitor of CYP17 which has demonstrated clinical efficacy in patients with CRPC. Currently, AA is administered with concomitant prednisone.
Study: NCT04235062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution
Description: A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Bolus Furosemide
Description: Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
Study: NCT00423865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day.
Study: NCT02922933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entinostat
Description: HDAC (histone deacetylase inhibitor)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entinostat
Description: HDAC (histone deacetylase inhibitor)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entinostat
Description: HDAC (histone deacetylase inhibitor)
Study: NCT02456883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: oral
Study: NCT02922933

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Proton pump inhibitor

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Proton pump inhibitor

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Histamine-2 blocker
Study: NCT00606944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fast-track rehabilitation
Description: fast-track rehabilitation with early ambulation and diet after elective colorectal resection
Study: NCT02456883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled gilteritinib
Description: oral
Study: NCT03518060

Intervention type: DRUG
Intervention: JULUCA
Description: JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
Study: NCT03554330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: (1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: (1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balloon atrial septostomy
Description: Graded balloon atrial septostomy is performed in all patients.
Study: NCT02339363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting Meditation
Description: 4 weeks Sitting Meditation
Study: NCT03929484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal reservoir cannula
Description: The experimental oxygen mask (nasal reservoir cannula) fits over a standard nasal cannula. The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.
Study: NCT02339363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: 4 weeks of Hatha yoga
Study: NCT01487499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg in 40 mL of normal saline for each of 4 bronchoscopies
Study: NCT02798406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNX-2401
Description: On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
Study: NCT03554330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon atrial septostomy
Description: Graded balloon atrial septostomy is performed in all patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon atrial septostomy
Description: Graded balloon atrial septostomy is performed in all patients.
Study: NCT04194697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No exercise
Description: No exercise program
Study: NCT04289402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized tDCS
Description: The participant will receive 10, 20-minutes sessions of personalized tDCS Monday-Friday, at approximately the same time of day, over two consecutive weeks.
Study: NCT01175837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies: Pre- and post-fasting side effect questionnaires
Study: NCT04289402

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Active-Sham
Description: The participant will receive 20, 20-minute sessions of active-sham stimulation Monday-Friday, at approximately the same time of day, over two consecutive weeks.
Study: NCT01175837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preventative dietary intervention
Description: 24, 36, or 48 hour fast prior to chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04082832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cu(II)ATSM
Description: oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: oral suspension
Study: NCT03656835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Nanotechnology
Description: Undergo ILN biochip testing
Study: NCT00443612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Hydrochlorothiazide
Description: Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Hydrochlorothiazide
Description: Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Administration of irbesartan 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Administration of irbesartan 150 mg/day
Study: NCT04867239

Intervention type: OTHER
Group type: OTHER
Intervention: A two-day education progra
Description: During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise.
Study: NCT04012918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine plus aromatase inhibitor
Description: Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A.I.
Description: aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor